Treatment for millions of Americans at stake in ‘skinny label’ Supreme Court case

The Supreme Court will soon decide a case that could upend the balance built into a bipartisan law that has accelerated the launch of generic drugs and saved American patients, employers, and taxpayers trillions of dollars in recent decades  — while still incentivizing biopharmaceutical companies to research and develop medicines in the first place.

The […] ...